Prognosis impact of multiple novel lymphocyte‐based inflammatory indices in patients with initially diagnosed coronary artery disease

Yi Gao,Geng Bai,Yuqing Li,Bo Yu,Ziqiang Guo,Xiaolin Chen,Tong Liu,Guangping Li
DOI: https://doi.org/10.1002/iid3.1340
2024-09-29
Immunity Inflammation and Disease
Abstract:SIIRI ≥ 247.170 × 1018/L2 is independently associated with MACEs in newly diagnosed CAD patients. Combining SIIRI with the traditional risk factors model can better predict MACEs. Background This study aimed to evaluate six novel lymphocyte‐based inflammatory markers (neutrophil‐lymphocyte ratio, monocyte‐lymphocyte ratio, platelet‐lymphocyte ratio [PLR], systemic immune inflammation index [SII], systemic inflammatory response index, and systemic immune inflammation response index [SIIRI]) in patients with newly diagnosed coronary artery disease [CAD]. Methods A total of 959 patients newly diagnosed with CAD and underwent diagnostic coronary angiography were enrolled in this study and followed for major adverse cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The best cutoff value was used to compare the six indicators. Cox risk regression analysis evaluated the relationship between novel lymphocyte‐based inflammatory markers and MACEs in newly diagnosed CAD patients. Results During a mean follow‐up period of 33.3 ± 9.9 months, 229 (23.9%) MACEs were identified. Multivariate Cox regression analysis showed that only SIIRI (hazard ratio [HR]: 5.853; 95% confidence interval [CI]: 4.092–8.371; p
immunology
What problem does this paper attempt to address?